Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma

CompletedOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

November 12, 2014

Primary Completion Date

October 17, 2018

Study Completion Date

October 17, 2018

Conditions
Mycosis Fungoides
Interventions
DRUG

Valchlor

Valchlor gel 0.016%

Trial Locations (36)

10032

Investigator Site, New York

10467

Investigator Site, The Bronx

11203

Investigator Site, Brooklyn

14450

Investigator Site, Fairport

15213

Investigator Site, Pittsburgh

19104

Investigator Site, Philadelphia

19107

Investigator Site, Philadelphia

19341

Investigator Site, Exton

22031

Investigator Site, Fairfax

29414

Investigator Site, Charleston

30328

Investigator Site, Atlanta

33021

Investigator Site, Hollywood

33134

Investigator Site, Coral Gables

33612

Investigator Site, Tampa

34102

Investigator Site, Naples

39216

Investigator Site, Jackson

44106

Investigator Site, Cleveland

48103

Investigator Site, Ann Arbor

60611

Investigator Site, Chicago

60612

Investigator Site, Chicago

60637

Investigator Site, Chicago

63104

Investigator Site, St Louis

63110

Investigator Site, St Louis

70112

Investigator Site, New Orleans

72205

Investigator Site, Little Rock

75231

Investigator Site, Dallas

75390

Investigator Site, Dallas

80045

Investigator Site, Aurora

89074

Investigator Site, Henderson

91010

Investigator Site, Duarte

91941

Investigator Site, La Mesa

92701

Investigator Site, Santa Ana

94115

Investigator Site, San Francisco

06520

Investigator Site, New Haven

02215

Investigator Site, Boston

08520

Investigator Site, East Windsor

All Listed Sponsors
lead

Helsinn Therapeutics (U.S.), Inc

INDUSTRY

NCT02296164 - Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma | Biotech Hunter | Biotech Hunter